Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Temozolomide with or without SHR-1316 in Relapsed SCLC
NCT04400188Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluzoparib in small cell lung cancer (SCLC) (2 arms), sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity at 21 days, Recommended Phase II Dose at 2 years and 2 more. Started Jun 2020; status: completed.
02
Drugs
fluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04400188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400188.